Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Receives Consensus Recommendation of “Hold” from Analysts

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) has earned an average rating of “Hold” from the five research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $38.3333.

A number of equities analysts have recently commented on PHAR shares. Wall Street Zen downgraded shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Oppenheimer reaffirmed an “outperform” rating and set a $41.00 price objective (down from $42.00) on shares of Pharming Group in a report on Friday, March 13th. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a report on Tuesday, March 24th. Weiss Ratings downgraded shares of Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Finally, Canaccord Genuity Group started coverage on shares of Pharming Group in a report on Friday, April 10th. They set a “buy” rating and a $37.00 price objective for the company.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. NewEdge Advisors LLC increased its stake in shares of Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after buying an additional 28,615 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Pharming Group in the fourth quarter valued at $360,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Pharming Group in the fourth quarter valued at $224,000. Finally, EverSource Wealth Advisors LLC acquired a new stake in shares of Pharming Group in the second quarter valued at $32,000. 0.03% of the stock is currently owned by institutional investors and hedge funds.

Pharming Group Stock Up 1.3%

Shares of PHAR stock opened at $12.87 on Wednesday. Pharming Group has a 12 month low of $9.54 and a 12 month high of $21.34. The firm has a market cap of $908.88 million, a PE ratio of 80.44 and a beta of -0.04. The stock has a 50 day moving average of $14.11 and a 200-day moving average of $15.98. The company has a quick ratio of 2.06, a current ratio of 2.63 and a debt-to-equity ratio of 0.35.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.12). The business had revenue of $72.45 million for the quarter, compared to analyst estimates of $92.06 million. Pharming Group had a return on equity of 4.64% and a net margin of 3.30%. On average, equities analysts predict that Pharming Group will post 0.6 EPS for the current year.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.